Nevertheless, the rejection of HSC4, HCC827, or NCI-H1975 by nivolumab in huNOG-FcγR−/− mice suggests that tumor-derived antigens activate allo-HLA reactive T cells, even if they are restricted by mouse MHC, to invoke anti-tumor immune reactions. This evidence concerns the gene FCGR2A and neoplasm.